Research Foundation

Publications

Annually, the HDA Research Foundation undertakes research projects to educate and inform pharmaceutical supply chain stakeholders as they work daily to achieve healthcare efficiencies. The publications featured in this section may be downloaded at no additional cost from HDA's Resources webpage.

HDA Factbook: The Facts, Figures and Trends in Healthcare

In its 89^th year, the HDA Factbook provides data metrics and benchmarking on the traditional pharmaceutical supply chain.

Sponsors: Apotex Corp. and Real Value Rx dba Hospital Pharmaceutical Consulting (Silver); Amneal Pharmaceuticals, IQVIA and Pharmacy First. (Bronze)

Specialty Pharmaceutical Distribution: Facts, Figures and Trends

The Specialty Pharmaceutical Distribution: Facts, Figures and Trends report is a go-to resource for benchmarking data on specialty distribution and insight into the specialty pharmaceutical marketplace.

Sponsors: Genentech, A Member of the Roche Group and Value Drug Company (Silver); Amneal Biosciences, Bristol-Myers Squibb Company and Takeda Pharmaceuticals America, Inc. (Bronze)

“The 340B Drug Pricing Program: Evolution and Looking Forward”

Since 1992, the 340B Drug Pricing Program has played a modest, but increasingly important, role in the U.S. healthcare market. This whitepaper provides a brief overview of the program since inception; the impact of the program on various stakeholders; and presents a forward-looking view on the program given recent public reports and discussion, administration actions and potential legislative changes.

"Change Management: Best Practices in Contract and Chargeback Administration" Whitepaper

In the fall of 2018, the Foundation partnered with Rutgers University's Supply Chain Management Graduate Program. A team of five students, under the direction of Professor Irene Gerlovin, worked to identify and describe best practices for managing change in contract and chargeback administration due to system conversions and company mergers and acquisitions. The students interviewed subject matter experts, generated a survey, analyzed the data and developed a whitepaper. The final project was presented to HDA members through a webinar.

Sponsors: Amneal Pharmaceuticals, IQVIA and WDSrx - Woodfield Distribution, LLC.

The Role of Reverse Distribution

Through industry knowledge, interviews and survey results, The Role of Reverse Distribution report highlights the complex reverse distribution process and opportunities for future enhancement.

Sponsors: PharmaLink, Inc. (Silver); Guaranteed Returns (Bronze)

"Biosimilars: The State of the U.S. Market"

This report analyzes the current market for biosimilars in the U.S. through interviews conducted with senior executives from specialty pharmaceutical manufacturing and distribution companies.

"Understanding Pharmaceutical Distribution" Presentation

This turnkey PowerPoint presentation for presenters/trainers, as well as industry stakeholders, examines how the pharmaceutical supply chain operates and discusses the economics of traditional distribution.

"Understanding Specialty Distribution" Presentation

This turnkey PowerPoint presentation for presenters/trainers, as well as industry stakeholders, examines how the specialty pharmaceutical supply chain operates and discusses the economics of specialty pharmaceutical distribution.

"Manufacturer Serialization Readiness Survey"

Conducted in fall 2018, this survey details pharmaceutical manufacturers’ readiness to meet the product serialization requirements of the Drug Supply Chain Security Act (DSCSA), including when distributors can expect to begin receiving serialized product and associated data.

Sponsors: LSPediA and WDSrx - Woodfield Distribution, LLC.

The Role of Distributors in the U.S. Specialty Pharmaceuticals Value Chain

Through interviews, survey work and secondary data, The Role of Distributors in the U.S. Pharmaceuticals Value Chain explores the critical role distributors play to ensure the efficient and effective distribution of specialty medications.

Sponsors: Anda Inc.; Boehringer Ingelheim Pharmaceuticals, Inc. ; H. D. Smith; and Takeda Pharmaceuticals America, Inc.